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Abstract 
This report describes the interdisciplinary
approach  and  solving  algorithm  of  a  DIN
9001:2000 certified tumor board in managing a
giant-size type-B2 thymoma IIb in an elderly
patient. The process of managing the thymoma
with specialists of surgery, internal medicine,
radiology, and pathology until finally extirpa-
tion  and  continuous  follow-up  is  described.
Respective  computerized  tomography  scans,
histology, macro-pathology, and operative pic-
tures of the case are provided as well as an up-
to-date literature review.
Introduction
We report an extirpation of a giant-size type-
B2-thymoma  IIb,  according  to  the  modified
clinical  Masaoka
1,2 and  histological  WHO
3,4
stages. Previously a period of controlled obser-
vation  by  an  interdisciplinary  and  DIN
9001:2000  certified  tumor  conference  team
was pursued. Our case report is supported by
histological,  macroscopic,  and  computerized
tomography (CT) pictures.
Case Report
An  82-year-old  woman  presented  with  a
cough  enduring  for  weeks  and  a  feeling  of
thor  acic pressure. Anamnestically the patient
had no history of severe thoracic illness. On
clinical admission, routinely collected labora-
tory values – including leukocytes – were nor-
mal. A chest CT scan with intravenous contrast
was performed and depicted a solid tumor of
about  10¥5¥6  cm  in  the  superior  anterior
mediastinum. The tumor was located in the
immediate vicinity of the pericardium above
the aortic arch and superior vena cava, with no
signs of infiltrative growth. CT-acquired histol-
ogy via Biopince (Amgiotech, Medical Device
Technologies Inc., Florida, USA; 10 cm, 18ga)
revealed  a  thymoma  as  the  diagnosis.  The
post-diagnosis  algorithm  for  adequate  treat-
ment of the patient included an interdisciplin  -
ary and DIN 9001:2000 certified tumor confer-
ence with specialists of surgery, internal med-
icine,  radiology,  and  pathology.  Because  the
patient’s  symptoms  were  ameliorated,  and
especially given her age, it was decided first to
pursue  a  wait-and-see  strategy.  Half  a  year
later the patient presented again. A new CT
scan revealed an increase in the size of the
thymoma  to  10¥6¥10  cm.  The  continuous
growth  increasingly  affected  cardiovascular
structures in the mediastinum (Figure 1). The
trachea was not deviated and the underlying
diaphragm  did  not  appear  paralytic.  It  was
decided to extirpate the tumor surgically, tak-
ing into account the increased risk of surgical
interventions, especially in elderly patients.
The surgical procedure lasted for about 150
min.  It  included  a  complete  sternotomy  and
mobilization  of  the  tumor  per  continuitatem
from caudal to cranial, and finally extirpation
(Figure 2). Grossly, the tumor was adherent to
the mediastinal pleura and pericardium without
invading these structures. It was fed partly by
one branch of the right internal thoracic artery
– visible in the CT scan – that had to be occlud-
ed surgically. One Redon drain (10 Ch.) was
placed dorsal to the sternum and one pleural
drain (24 Ch.) was placed on each side as well.
Macroscopically, the biggest part of the deli-
cately encapsulated, knotty, and mainly solid
tumor measured 75¥70¥55 mm. For histo- and
macro-pathological post-processing, the thym  -
oma was cut into slices (Figure 3). In general,
the  cutting  area  depicted  was  of  a  homo  -
genous,  brown  appearance,  with  some  focal
cystic and some hemorrhagic lesions of a max-
imum of 15 mm. Adjacent extirpated soft tissue
measured 120¥75¥20 mm. Microscopically, the
tumor  presented  a  lobular  architecture.
Multiple polygonal cells with large nuclei and
prominent nucleoli could be identified (Figure
4A).  Immunohistochemically,  a  Pan-CK  and
CK19 expression could be identified (Figure
4B) as well as a concomitant infiltrate of part-
ly CD3-positive lymphocytes (Figure 4C). The
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Figure 1. Intravenous chest CT scan.
(A) Axial view. Note the vicinity of the
tumor  (*)  to  the  internal  thoracic
artery (arrow). (B) Sagittal view. Note
the delicate location of the tumor (*)
above  the  right  atrium  (#).  (C)
Coronal view. Note the vicinity of the
tumor (*) to the mediastinal cardiovas-
cular structures such as the ascending
aorta and aortic arch (+), right atrium
(#), and left brachiocephalic vein (~).[Rare Tumors 2010; 2:e30] [page 83]
lymphocytological proliferation rate MIB1 aver-
aged 80% (Figure 4D).
In the final pathological classification, the
tumor was staged type-B2 thymoma IIb accord-
ing to the modified clinical Masaoka
1,2 and his-
tological WHO
3,4 stages. As expected, CRP rose
post-intervention  to  a  maximum  of  11.54
mg/dL (<0.5) on day 4 and decreased there-
after, to 6.67 mg/dL on day 5. The postoperative
course  was  ceteris  paribus uneventful.  The
patient was discharged on postoperative day 6.
Follow-up  studies  up  to  this  date  have  not
revealed any recurrence of the tumor and will
be continued.
Discussion
Thymomas  have  a  prevalence  of  0.1-
0.4/100,000.
5 They account for about 0.2-1.5%
of all malignant tumors and for about 50% of all
tumors in the upper ventral mediastinum; dis-
tribution between sexes is about equal, and
the majority of patients are aged between 40
and 60 years.
6 Thymomas are epithelial tumors
generally considered to have an indolent and
slow growth pattern, but should be regarded as
malignant nonetheless because of the poten-
tial for local invasion and, less often, systemic
metastases. 
One third of thymomas is detected casually
in body imaging, one third of patients presents
with  local  symptoms,  and  one  third  is  diag-
nosed  within  myasthenia  gravis  evaluation.
6
The  latter  seems  especially  noteworthy  as
other  paraneoplastic  autoimmune  diseases
occur  only  occasionally;  for  example,  with
small  cell  lung  cancers  or  gynecological
tumors, whereas myasthenia gravis is associ-
ated  with  thymomas  in  at  least  30%  of
patients.
7 Ectopic cervical thymomas are a rare
and diagnostically challenging entity that fre-
quently is misdiagnosed on fine needle aspir  -
ation cytology and frozen sections.
8
The most commonly used classification of
thymomas was initially introduced by Masaoka
et al.
1 in 1981, and describes four stages of
thym  oma with special reference to the clinical
stage.  The  most  recent  modifications  were
published in 2003
3 and included more histolog-
ical data. Generally, recurrences after complete
surgical  resection  are  rare  but  have  been
described  in  the  literature.
9-11 Spontaneous
tumor regression of invasive thymoma
12as well
as of thymoma-associated immunodeficiency
have been described as well.
13
The effect of radiation therapy is discussed
controversially.  It  is  generally  agreed  that
patients with a Masaoka III stage and higher
benefit  from  radiation  therapy.  Chen  et  al.
state that adjuvant radiotherapy after complete
tumor  resection  for  patients  with  stage  II
thym  oma  neither  reduced  recurrence  rates
significantly,  nor  improved  survival  rates.
14
Several prognostic factors for thymic tumors,
including the Masaoka stage, WHO histology,
complete resection, great vessel invasion, and
size of thymoma have been identified.
15 In a
recent publication, Wright et al. demonstrated
that thymoma size is an independent risk fac-
tor and tumors measuring >8 cm were found
to be recurrent in 29%,
16 further justifying con-
tinuous follow-up studies of the patient pre-
sented. Tumor size of >11 cm as well as the
histological type-B3 thymoma
14 have also been
described as significant independent prognos-
tic variables.
17 Concerning prognostic indica-
tors after surgery for thymoma, Okereke et al.
recently stated that long-term disease-specific
survival can be expected not only after surgery
for early-stage thymoma but also after surgery
for advanced disease, including patients with
pleural  metastases  but  limited,  however,  by
patients who undergo surgery for stage IV-A
disease, who do have reduced disease-free sur-
vival.
18 If the tumor is indeed malignant, the
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Figure 2. Intraoperative photograph of the
recently extirpated thymoma.
Figure 3. Cross-section preparation photo-
graph  of  the  macro-pathological,  post-
processed,  delicately  capsulated,  knotty,
and mainly solid thymoma.
Figure 4. (A) Neoplastic epithelial cells of the thymoma in a lymphocytic background
(Giemsa stain; 200X magnification). (B) Immunohistochemical expression of cytoker-
atin 19 highlights the neoplastic epithelial component (CK19; 100X magnification). (C)
Perivascular accumulation of mature CD3-positive T-lymphocytes (CD3; 100x magnifi-
cation). (D) High proliferative activity, sparing areas of accumulated mature T-lympho-
cytes (MIB1; 50X magnification).[page 84] [Rare Tumors 2010; 2:e30]
risk of lymph node metastasis generally is esti-
mated to be 1.8% and does not seem to impact
on overall survival rate.
19
Twenty-year survival rates of type II thym  -
omas, according to the Masaoka staging sys-
tem, are reported to be 91%.
20 Thymomas of the
presented giant size are extremely rare. It is
noteworthy that the delicate size and location
of the tumor and the age of our patient neces-
sitated deliberate surgical intervention.
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